Lauding the government’s initiative of unveiling a National Biotechnology Policy, industry experts said that it was imperative that this policy was implemented in a time bound manner and that the government ensured that it “walked the talk” if the industry had to reap the benefits of the policy. Calling for a single window regulatory authority, industry voices said that the system should truly be a single window system without companies having to interface with other layers of authorities and efforts have to be taken to ensure that the funds sanctioned to small entrepreneurs was not bundled along with red tape and bureaurcatic hurdles. The policy should trigger an atmosphere for innovation and nurturing innovation. Encouraging entrepreneurs and business focus in BT by bringing investments into the sector and developing spin offs was some of the key elements that were required to grow the industry. Creating an ambience that was conducive to global partnering in terms of bringing clinical research to India and developing it as an R and D hub as well as a centre of academic excellence were other focus points. The policy, it was noted, had underlined the importance of the private sector in nation building by taking the initiative of commiting to spend 30 percent of DBT’s annual funds on private public projects.